US equities |
MU $795.41 ▲+0.02% SNDK $1,037.40 ▲+0.00% NVDA $200.13 ▲+0.00% AMD $488.78 ▲+0.00% SPCX $135.92 ▲+0.00% TSLA $385.19 ▲+0.00% SKHY $143.07 ▲+0.00% AMZN $266.03 ▲+0.00%
FinancialContent

NLS Pharmaceutics Ltd. - Warrant (NQ:NLSPW)

0.0179 UNCHANGED
Last Price Updated: 3:17 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NLS Pharmaceutics Ltd. - Warrant

< Previous 1 2 3 4 Next >
News headline image
NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
News headline image
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled
STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
News headline image
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation
STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
News headline image
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy
Planned Phase 2a clinical trial anticipated to commence in August 2021 STANS, SWITZERLAND / ACCESSWIRE / July 15, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
< Previous 1 2 3 4 Next >